Rational Advisors’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.15M | Sell |
4,574
-1,323
| -22% | -$285K | 0.11% | 82 |
|
|
2026
Q1 | $1.28M | Buy |
5,897
+994
| +20% | +$220K | 0.13% | 77 |
|
|
2025
Q4 | $1.12M | Buy |
4,903
+717
| +17% | +$163K | 0.11% | 87 |
|
|
2025
Q3 | $969K | Buy |
4,186
+1,805
| +76% | +$368K | 0.1% | 85 |
|
|
2025
Q2 | $442K | Buy |
2,381
+534
| +29% | +$99.2K | 0.04% | 103 |
|
|
2025
Q1 | $387K | Sell |
1,847
-1,318
| -42% | -$256K | 0.04% | 106 |
|
|
2024
Q4 | $562K | Buy |
+3,165
| New | +$582K | 0.06% | 91 |
|
|
2024
Q3 | – | Sell |
-1,473
| Closed | -$253K | – | 171 |
|
|
2024
Q2 | $253K | Buy |
+1,473
| New | +$244K | 0.02% | 98 |
|
|
2023
Q3 | – | Sell |
-188
| Closed | -$25.3K | – | 276 |
|
|
2023
Q2 | $25.3K | Hold |
188
| – | – | ﹤0.01% | 194 |
|
|
2023
Q1 | $30K | Sell |
188
-11,347
| -98% | -$1.73M | ﹤0.01% | 184 |
|
|
2022
Q4 | $1.86M | Sell |
11,535
-3,828
| -25% | -$587K | 0.15% | 52 |
|
|
2022
Q3 | $2.06M | Buy |
15,363
+2,884
| +23% | +$414K | 0.16% | 45 |
|
|
2022
Q2 | $1.91M | Buy |
12,479
+12,297
| +6,757% | +$1.88M | 0.14% | 51 |
|
|
2022
Q1 | $30K | Sell |
182
-9,015
| -98% | -$1.31M | ﹤0.01% | 171 |
|
|
2021
Q4 | $1.25M | Sell |
9,197
-5,255
| -36% | -$621K | 0.08% | 85 |
|
|
2021
Q3 | $1.56M | Buy |
14,452
+3,634
| +34% | +$415K | 0.12% | 60 |
|
|
2021
Q2 | $1.22M | Sell |
10,818
-1,890
| -15% | -$213K | 0.14% | 88 |
|
|
2021
Q1 | $1.38M | Buy |
12,708
+2,133
| +20% | +$228K | 0.25% | 74 |
|
|
2020
Q4 | $1.13M | Sell |
10,575
-2,120
| -17% | -$204K | 0.3% | 83 |
|
|
2020
Q3 | $1.11M | Sell |
12,695
-470
| -4% | -$44.2K | 0.48% | 75 |
|
|
2020
Q2 | $1.29M | Buy |
+13,165
| New | +$1.16M | 0.67% | 45 |
|
|
2020
Q1 | – | Sell |
-7,529
| Closed | -$666K | – | 160 |
|
|
2019
Q4 | $666K | Buy |
7,529
+4,704
| +167% | +$391K | 0.31% | 93 |
|
|
2019
Q3 | $213K | Sell |
2,825
-216
| -7% | -$14.8K | 0.08% | 222 |
|
|
2019
Q2 | $221K | Buy |
3,041
+1,381
| +83% | +$109K | 0.08% | 204 |
|
|
2019
Q1 | $134K | Sell |
1,660
-1,319
| -44% | -$108K | 0.04% | 233 |
|
|
2018
Q4 | $275K | Sell |
2,979
-3,129
| -51% | -$275K | 0.09% | 154 |
|
|
2018
Q3 | $578K | Buy |
6,108
+5,095
| +503% | +$483K | 0.14% | 144 |
|
|
2018
Q2 | $94K | Buy |
1,013
+848
| +514% | +$82.8K | 0.04% | 241 |
|
|
2018
Q1 | $16K | Buy |
+165
| New | +$18.1K | 0.01% | 337 |
|
|
2017
Q4 | – | Sell |
-3,100
| Closed | -$275K | – | 263 |
|
|
2017
Q3 | $275K | Sell |
3,100
-6,000
| -66% | -$457K | 0.15% | 156 |
|
|
2017
Q2 | $660K | Buy |
+9,100
| New | +$612K | 0.41% | 92 |
|
|
2015
Q3 | $1.27M | Buy |
23,311
+13,500
| +138% | +$879K | 0.51% | 80 |
|
|
2015
Q2 | $659K | Sell |
9,811
-14,950
| -60% | -$976K | 0.21% | 121 |
|
|
2015
Q1 | $1.45M | Sell |
24,761
-204
| -0.8% | -$12.3K | 0.35% | 99 |
|
|
2014
Q4 | $1.63M | Buy |
+24,965
| New | +$1.57M | 0.32% | 103 |
|
|
2013
Q4 | $373K | Sell |
7,070
-45,991
| -87% | -$2.26M | 0.03% | 388 |
|
|
2013
Q3 | $2.37M | Sell |
53,061
-1,208
| -2% | -$53.5K | 0.18% | 173 |
|
|
2013
Q2 | $2.24M | Buy |
+54,269
| New | +$2.37M | 0.19% | 186 |
|
Other funds holding ABBV
Rational Advisors's ABBV Position: Q2 2026 in Review
Rational Advisors reduced its AbbVie (ABBV) stake by 22% in Q2 2026, selling an estimated $285K and leaving 4,574 shares worth $1.15M. The position accounts for 0.11% of the portfolio, ranked #82.
Rational Advisors first reported a position in ABBV in Q2 2013 and has held it in 38 quarters since. The position peaked at $2.37M in Q3 2013. 4,201 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Rational Advisors held 4,574 shares of AbbVie worth $1.15M as of Q2 2026.
- Rational Advisors sold 1,323 AbbVie shares in Q2 2026, an estimated $285K.
- AbbVie made up 0.11% of Rational Advisors's portfolio in Q2 2026, its #82 holding.
- Rational Advisors first reported a position in AbbVie in Q2 2013 and has held it in 38 quarters since.
- Rational Advisors's AbbVie position peaked at $2.37M in Q3 2013.
- 4,201 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Rational Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.